OUR PURPOSE PIONEERING SCIENCE PATIENTS OUR PEOPLE ENVIRONMENT COMMUNITY REPORTING 48 ADVANCING HEALTH ACCESS AND EQUITY BIOGEN 2021 YEAR IN REVIEW Increasing representation in clinical trials To ensure therapies work on people of all backgrounds, we are focused on more inclusive clinical trial enrollment. To help achieve these goals, we have made investment to work to address the systemic barriers to clinical study participation, bringing our trials into communities where clinical trials have historically not been offered to help ensure our trials are available to underrepresented patients and their families, as well as to work with trusted organizations and leaders at the national and local levels to make an impact to drive health equity. SPOTLIGHT #MyBaseballMemory raises awareness of Alzheimer’s disease “It’s Time” by Biogen, Eisai and the Negro Leagues Baseball Museum (NLBM) launched a new campaign: #MyBaseballMemory. It was designed to carry the excitement of baseball beyond hometown teams while spotlighting an important health education message. The campaign encouraged celebrities and fans to share their favorite baseball memory on social media using #MyBaseballMemory while raising awareness of Alzheimer’s disease. Since the Negro Leagues no longer exist, NLBM keeps their legacy alive by sharing memories. These memories also help highlight the importance of cognitive brain health and advance Biogen’s disease-state education goals, reinforcing the importance of knowing the early signs of mild cognitive impairment (MCI) due to Alzheimer’s disease. With Black, African American, Hispanic and Latino communities disproportionately impacted by Alzheimer’s disease, the #MyBaseballMemory campaign is another way we are working to advance our commitment to health equity. DE&I STRATEGY #3 Improve health outcomes for Black, African American, Hispanic, Latino and other underserved communities in the disease areas we treat Inadequate representation in clinical trials contributes to health disparities which negatively impact health outcomes. GOAL MEET INDUSTRY DIVERSITY BENCHMARKS in clinical trials and medical publications on underserved and underrepresented communities. PROGRESS In 2021, 100% of our Phase 1–4 studies in the U.S., led by Global Clinical Operations, included a plan to recruit participants from underrepresented communities to ensure the study population is representative of the intended treatment population. Our progress also included expanding our Community Advisory Board (CAB), which received the Reuters Global Pharma Patient Champion Award, to include representation from Asian American, Pacific Islander and Native American communities. We sustained community outreach and education programs, including with community-based programs. Our progress included developing educational assets for clinical trials sites, introducing a demographic distribution dashboard, benchmarking diversity and disparities among clinical trials as members of the Investigative Site Diversity Initiative for Tufts Center for the Study of Drug Development sites and more. We also expanded understanding with our employees with events like our Healthy Equity Cafe Series and launched DE&I training. Þ READ MORE ABOUT OUR DE&I STRATEGY